Advertisement

Pharmacy

When compared to chemotherapy, a drug targeting oncogenic RAS mutations extended overall and progression-free survival for patients with metastatic pancreatic cancer, according to a study published May 31 in The New England Journal of Medicine. The third-leading cause of cancer…

The Supreme Court has unanimously ruled that generic drugmakers cannot be sued for patent infringement simply because their marketing materials don’t spell out every limitation of their FDA approval — a decision that clears a significant legal cloud over a…

Winston-Salem, N.C.-based Novant Health has launched NovaCatalyst, a venture designed to expand its pharmacy and imaging services to healthcare organizations nationwide. NovaCatalyst will support the growth of MedVenta, a provider-led pharmacy solutions company, and MedQuest Imaging, an outpatient imaging provider,…

Active drug shortages in the U.S. rose for the second consecutive quarter in 2026, reaching 223 in the first quarter, according to the American Society of Health-System Pharmacists — and the FDA’s database continues to reflect new discontinuations weekly. The…

Rockford, Ill.-based Mercyhealth has opened a retail pharmacy in Beloit, Wis., expanding prescription access for patients on the Illinois-Wisconsin border.  The pharmacy offers prescription filling, medication counseling, prescription transfers and refill services. A drive-thru lane is available for patients seeking…

Advertisement

Researchers at the University of California, Irvine, have found that some antibody-drug conjugates, an emerging class of targeted cancer therapies, were associated with serious infection-related complications, including hospitalization and intensive care admissions. The study analyzed treatment data from 3,511 patients…

Rockford, Ill.-based Mercyhealth has opened a new pharmacy in Beloit, Wis., expanding access to prescription services for patients in the community, according to a June 2 report from WIFR. Mercyhealth Pharmacy-Beloit is one of 11 pharmacies operated by the health…

The FDA has issued a complete response letter for Cingulate’s new drug application seeking approval of CTx-1301 for the treatment of attention-deficit/hyperactivity disorder. The agency’s response identified specific Chemistry, Manufacturing and Controls information requests and did not raise any current…

Advertisement